Compare J B Hunt Transport Services Inc (JBHT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Regeneron Pharmaceuticals Inc — how do they compare? J B Hunt Transport Services Inc trades at $292.21 (market cap $27.36B), while Regeneron Pharmaceuticals Inc trades at $671.6 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.6× J B Hunt Transport Services Inc's market cap, and J B Hunt Transport Services Inc pays the higher dividend (0.62%). Which is the better fit depends on your goals.
| JBHT | REGN | |
|---|---|---|
Market Cap | $27.36B | $70.47B |
Sector | Industrials | Health |
52-Week High | $298.41 | $812.27 |
52-Week Low | $130.65 | $545.46 |
Enterprise Value | $28.50B | $64.42B |
Dividend Yield | 0.62% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $290.43, down 0.34% today but near its 52-week high, with a bullish technical outlook and consistent earnings beats. The stock shows strong momentum, supported by intermodal growth and cost discipline. Recent Q2 2026 EPS of $1.91 beat estimates by 12%, driving positive sentiment. Valuation remains elevated with a P/E of 41.45, reflecting high growth expectations amid industry capacity constraints.
Outlook is positive due to structural freight market shifts and operational efficiency, but risks include premium valuation sensitivity and economic cyclicality. Analyst consensus favors Buy with a $299.82 target, suggesting modest upside. Investors should weigh robust fundamentals against potential margin pressures from rising costs.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
